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Summary: The aim of this article is to propose guidelines and recommendations in
problematic areas in pathologic reporting of endometrial carcinoma (EC) regarding
special techniques and ancillary studies. An organizing committee designed a
comprehensive survey with different questions related to pathologic features, diagnosis,
and prognosis of EC that was sent to all members of the International Society of
Gynecological Pathologists. The special techniques/ancillary studies group received 4
different questions to be addressed. Five members of the group reviewed the literature
and came up with recommendations and an accompanying text which were discussed and
agreed upon by all members of the group. Twelve different recommendations are made.
They address the value of immunohistochemistry, ploidy, and molecular analysis for
assessing prognosis in EC, the value of steroid hormone receptor analysis to predict
response to hormone therapy, and parameters regarding applying immunohistochemistry
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In the western world, endometrial carcinoma (EC) is
the fourth most common cancer among women, with
an estimated incidence of 10 to 20 per 100,000 women.
Although the prognosis is favorable for patients with
low-grade tumors and early-stage disease, the outcomes
for patients with high-grade and/or advanced stage
tumors remains relatively poor. Following surgery
(which is the usual treatment), patients with tumors
with a high risk of recurrence often receive adjuvant
radiotherapy, chemotherapy, and/or hormone therapy.
However, traditional chemotherapeutic regimes are less
effective in comparison with cancers of other organs,
which emphasize the importance of identifying new
molecular targets. Several biomarkers have been
proposed to better assess the prognosis and prediction
of response to therapy and to identify patients carrying
germline mutations associated with an increased risk of
EC (1). However, there is no consensus regarding the
application of these biomarkers in clinical practice.
In this article, we provide guidelines, which have
been produced after a thorough literature search, and
discussed among a group of members of the Interna-
tional Society of Gynecological Pathologists (ISGyP),
selected because of their expertise in the immunohis-
tochemistry (IHC) and molecular pathology of EC.
METHODS
An organizing committee composed of 5 of the
authors (W.G.M., V.P., A.M., E.O., and X.M.G.)
was chosen by the Executive Committee of ISGyP.
The committee designed a survey (see paper on
survey) with many different questions, related to the
pathologic features, diagnosis, and prognosis of EC,
which was sent to all members of ISGyP. After
analysis of the responses, the organizing committee
selected several problematic areas that would be
addressed, to achieve consensus and provide recom-
mendations. The organizing committee created 3
different groups: (1) diagnosis, (2) processing/sam-
pling/staging/prognosis, and (3) special techniques/
ancillary studies. Several questions were sent to
each group.
The special techniques/ancillary studies group ad-
dressed 4 different questions. Five members of the
group (T.A.L., B.C., I.M.S., L.H.E., and X.M.G.)
reviewed the literature and came up with recommen-
dations and accompanying text which were discussed
and agreed by all members of the group. Levels of
evidence and strength of the recommendations were
established according to criteria established in Table 1.
Question 1. Should IHC and Ploidy Analysis be
Performed for Assessing Prognosis in EC?
A preliminary comment is necessary to emphasize
that IHC is important in histologic typing, and this is
relevant for prognosis. This is particularly important
for high-grade EC, including high-grade endometrioid
carcinoma (EEC), serous carcinoma (SC), and clear
cell carcinoma, since there is poor interobserver
agreement in diagnosing this subset of tumors (2).
These issues will be addressed by the diagnosis group.
Other than markers which are useful in diagnosis,
there are few speciﬁc studies that provide deﬁnitive
evidence for the routine use of IHC or ploidy analysis
in determining the prognosis of EC.
There has been considerable literature on the associ-
ation between prognosis and the IHC analysis of
estrogen receptor (ER), progesterone receptor (PR),
Ki67, and p53 in EC (3). It is well established that there
is an association between the expression of these markers
and prognosis and there is a signiﬁcant literature
regarding this (4–7), but there are a lack of large
prospective studies to determine their prognostic utility.
Hormone receptor status has been suggested to be a
relevant prognostic marker, and the presence of steroid
receptors correlates with low tumor grade, as well as
favorable outcome in some studies. However, there is no
absolute evidence that steroid hormone receptor analysis
should be incorporated into clinical practice.
Similar comments pertain to ploidy analysis. There
is some literature on the association of ploidy with
TABLE 1. Level of evidence and strength of recommendation
adapted from ESMO 2014 endometrial cancer consensus
conference
Level of evidence
I. Evidence from at least 1 large randomized control trial of
good methodological quality (low potential for bias) or
metaanalyses of well-conducted RCTs without heterogeneity
II. Small RCTs or large RCTs with a suspicion of bias (lower
methodological quality) or metaanalyses of such trials or of
trials with demonstrated heterogeneity
III. Prospective cohort studies
IV. Retrospective cohort studies or case-control studies
IV. Studies without control group, case reports, experts opinions
Strength of recommendation
A. Strong evidence for efﬁcacy with a substantial clinical beneﬁt,
strongly recommended
B. Strong or moderate evidence for efﬁcacy but with a limited
clinical beneﬁt, generally recommended
C. Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the
risk or the disadvantages (adverse events, costs, etc.) optional
D. Moderate evidence against efﬁcacy or for adverse outcome,
generally not recommended
E. Strong evidence against efﬁcacy or for adverse outcome, never
recommended
RCT indicates randomized clinical trials.
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prognosis, with promising results (8,9), but there
is a lack of deﬁnitive studies to determine its true
prognostic impact (10).
There are a number of additional potential bio-
markers reported for EC, but none of them are
validated for use as robust prognostic indicators. New
prognostic markers such as L1CAM (11,12) or Annexin
A-2 (13) are promising, but require prospective valida-
tion studies before bringing them into clinical practice.
Additional potentially useful markers are intratumoral
lymphocytes (CD8+), tumor-associated macrophages,
loss of ASRGL1, or hyaluronidase 1 (14,15). There is
particular interest regarding L1CAM and several studies
have validated this marker in multicentric analysis
(16,17).
One of the important issues with implementing
these markers in the routine clinical setting is the lack
of uniformity regarding the methodology used, both
technical and interpretive. Clearly, large prospective,
well deﬁned, uniform studies are needed to determine
the possible role of IHC for speciﬁc biomarkers and
ploidy analysis in the clinical setting.
Question 2. Should ER IHC be Used to Predict
Response to Hormone Therapy? Are There Any Other
Predictive Markers of Response to Hormone Therapy?
Hormone therapy is sometimes administered to
patients with advanced or recurrent EC, particularly
low-grade EEC (18). A wide range of hormonal
agents have been used, including medroxyprogester-
one acetate and synthetic progestational agents,
LHRH antagonists, tamoxifen, and new generations
of selective estrogen receptor modulators (19).
Although receptor IHC estimation has not been
universally accepted as the standard for prediction of
hormone response, several international guidelines
recommend determination of hormone receptor status
before hormone therapy is initiated (18).
A recent systematic review of 5 randomized trials
and 29 phase II studies, comprising a total of 2471
patients, concluded that hormone receptor assess-
ments should be carried out in all patients entered into
clinical trials, and may aid clinical management in
selected patients (20). The report notes that receptor-
negative status is not an absolute contraindication to
hormone treatment. Response rates to various hor-
monal treatments for EC patients are higher for
patients with low-grade EEC, and those with PR
expression. However, the methodology for assessing
and scoring hormone receptor expression in EC was
variable in the reported series.
Furthermore, changes in ER, and particularly PR,
expression occur during tumor progression, and ex-
pression is generally higher in primary in comparison
with metastatic tumors. This suggests that assessment of
ER status in the primary tumor may not reﬂect the
status in the recurrent or metastatic tumor and that
biopsies of recurrent or metastatic tumors with hormone
receptor analysis on these may be helpful (21).
In summary, at the present time there is not
enough data to support that the ER or PR status of
tumors, as determined by IHC, is a reliable marker
for predicting response to hormone therapy. There
are studies that have concluded that positive staining
does correlate with response, but other studies have
indicated that there is no correlation. Large pro-
spective studies using deﬁned, uniform approaches
need to be performed to determine whether ER and/
or PR IHC is a robust marker to predict hormone
therapy response.
Question 3. Should Molecular Analysis be Performed
to Diagnose and/or Classify Appropriately EC? When
Should This be Used and Which Analysis is
Recommended?
Tests based on sets of genes that are differentially
expressed in ECs compared with normal endometrium
cells have been proposed as adjuncts to diagnosis on
endometrial biopsies. They have been shown to be
useful in women with suspicion of cancer and
noninformative endometrial biopsies with insufﬁcient
material to allow a speciﬁc diagnosis.
Although promising, and assessed in prospective
studies (22), their incorporation into clinical practice
requires further validation.
There are different pathologic variants of EC.
Single-gene approaches have shown that the molec-
ular alterations involved in the development of EEC
are different from those of SC, clear cell carcinoma,
and carcinosarcoma. Many EECs exhibit micro-
satellite instability (MSI), as well as mutations in
PTEN, KRAS, and CTNNB1 whereas SC exhibits
alterations of TP53, widespread loss of heterozygos-
ity, as reﬂected by chromosomal instability, as well as
other molecular alterations (1).
The Cancer Genome Atlas (TCGA) Research
Network performed an integrated genomic character-
ization of EC (23). The genes most frequently mutated
in EEC were PTEN (77%), PIK3CA (53%), PIK3R1
(37%), CTNNB1 (36%), ARID1A (35%), KRAS (24%),
CTCF (20%), RPL22 (12%), TP53 (11%), FGFR2
(11%), and ARID5B (11%). The genes most frequently
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mutated in SC were TP53 (90.7%), PIK3CA (41.9%),
FBXW7 (30.2%), PPP2R1A (36.6%), CHD4 (16.3%),
CSMD3 (11.6%), and COLA 11 (11.6%) (1). Additional
studies using exome-sequencing analysis have also
shown mutations in TAF-1 (30%), in SC (24).
In addition to the TCGA approach, several groups
have assessed the usefulness of next-generation
sequencing in differential diagnosis between different
types of tumors, particularly EEC and SC (25). This
may be particularly interesting in tumors with non-
informative immunohistochemical results and ambig-
uous microscopic appearances. Further studies are
required to investigate whether next-generation se-
quencing is more accurate, informative, clinically
relevant, and cost-effective in comparison with IHC.
The TCGA exome sequence analysis revealed 4
groups of tumors with signiﬁcant differences in
prognosis. Group 1 comprised EEC with mutations
in POLE (ultramutated), associated with good
prognosis. Group 2 comprised EEC with MSI (hyper-
mutated) and group 3 tumors comprised EEC with
low copy number alterations; both groups 2 and 3
tumors showed similar and intermediate progression-
free survival rates. Group 4 (serous-like) tumors show
TP53 mutations, and a worse prognosis. They are
composed mostly of SCs, but also include some EEC
(many grade 3 but also some grades 1 and 2).
Following the TCGA study, sequencing of POLE
has been proposed to identify the group of ultra-
mutated tumors, which have been associated with an
excellent prognosis in several case series (26,27).
POLE sequencing seems to be particularly relevant
in the subgroup of patients with high-grade EEC,
particularly in those with some features mimicking SC
(28), although SC may also show POLE mutations
(29). Incorporation of POLE sequencing in the
assessment of endometrial tumors may have an
impact in tailoring treatment and possibly reducing
the extent of surgery, in a subset of patients with high-
grade ECs (30,31). Prospective studies are recom-
mended to assess the beneﬁts and cost-effectiveness of
POLE sequencing. Development of molecular tests
for POLE analysis is encouraged, particularly in
pathology departments with experience in molecular
pathology. Identiﬁcation of possible IHC surrogates
of POLE mutation in EC may also be of great
interest.
Combining POLE mutational analysis with IHC
analysis of p53 and mismatch repair (MMR) proteins
(PMS-2 and MSH-6) has been proposed to classify
ECs into the 4 TCGA groups. This is likely to be
particularly useful for high-grade EEC and SC, as a
surrogate assay that can replicate TCGA classiﬁcation
(30–32) (Table 2).
This topic will be also analyzed in another manu-
script. However, it is worth mentioning that there are
some aspects that should be taken into account. For
example, not all POLE-mutated EC are hypermutated.
Moreover, by performing MMR proteins IHC ﬁrst, we
will be missing some number of POLE-mutated cases.
Interpretation of p53 immunostaining will be also
discussed in a separate manuscript.
It is important to note that some tumors have
intermediate features (double mutant), and the
prognostic relevance of these unusual patterns will
require further analysis. Application of TCGA
surrogate classiﬁcation to high-grade EC may also
potentially help in deciding whether immunotherapy
is useful (33). Emerging data have suggested that
EECs exhibiting POLE mutations and MSI are
hypersensitive to the immune checkpoint inhibitor,
anti-PD-1, monotherapy because these tumors are
characterized by a high mutation load which produces
more neo-antigens. They also have a higher number of
tumor inﬁltrating lymphocytes (34–36). There is a
report of 2 cases of EC (1 POLE mutated, 1 MSH-6
mutated) both of whom were refractory to chemo-
therapy and radiation therapy, who both responded
(sustained partial response by RECIST criteria) to
nivolumab (37).
Addition of CTNNB1 (the gene coding for beta-
catenin) mutation analysis has also been proposed in
EEC with low copy number alteration, as a prognos-
tic biomarker in this subset of tumors (38).
Recent preclinical studies also demonstrate that
tumors with ARID1A mutations are more sensitive to
PARP1 inhibitors and EZH2 inhibitors (39,40). If the
results of future clinical trials show clinical beneﬁt,
analyzing ARID1A expression status (loss of expres-
sion is a surrogate for ARID1A inactivating mutation)
in EEC could be useful to stratify patients for
ARID1A-based therapy.
TABLE 2. Surrogate approach for applying TCGA scheme
into pathology practice
POLE mutation POLE mutated EC
(ultramutated)
POLE wild-type, p53 wild-type
pattern, abnormal mismatch repair
EC with microsatellite
instability (hypermutated)
POLE wild-type, p53 wild-type
pattern, normal mismatch repair
EC with low copy number
alterations
POLE wild-type, p53 abnormal
expression and normal mismatch
repair
Serous-like (high-copy
number) EC
EC indicates endometrial carcinoma; TCGA, The Cancer Genome
Atlas.
S117GUIDELINES SPECIAL TECHNIQUES GROUP
Int J Gynecol Pathol Vol. 38, No. 1 Supplement 1, January 2019
Question 4. Should IHC and/or MSI (Including
Methylation Analysis) be Performed Routinely in
Apparently Sporadic ECs? All Cases? When?
Approximately 3% to 5% of ECs can be attributed
to Lynch syndrome (LS) which is caused by germline
mutations in DNA MMR genes (MLH1, MSH-2,
MSH-6, PMS-2). Patients with LS have a 40% to 60%
lifetime risk for endometrial and colon cancer (41–43).
The identiﬁcation of LS in women with EC can lead
to the prevention of a second cancer in the patient and
incident cancers in family members through risk-
reducing strategies and heightened surveillance
(44,45). Utilization of clinical criteria to identify
patients with LS has less than optimal sensitivity
and efﬁciency.
A Society of Gynecologic Oncologists Clinical
Practice Statement in 2014 recommended all women
diagnosed with EC undergo systematic clinical screen-
ing (review of personal and family history) and/or
molecular or IHC screening for LS (46). In this
statement IHC screening of EC for LS is stated to be
the preferred screening strategy when resources are
available for the following reasons.
Systematic clinical screening, including a focused
personal and family history, will miss a signiﬁcant
fraction of women with LS who do not have a
suggestive family history (47–51). Some studies
indicate that up to 75% of LS patients are missed
using the revised Bethesda guidelines. It has been
proposed that the more sensitive strategy involves
universal tumor testing for either all endometrial
cancers or cancers diagnosed at age <60 (or 70),
regardless of personal or family cancer history.
Although EC can be screened for LS using IHC for
the 4 MMR proteins (MLH1, MSH-2, MSH-6, PMS-
2) and/or MSI analysis, with reﬂex MLH1 hyper-
methylation testing, IHC is the most cost-effective
method and is widely available in almost all
pathology laboratories. IHC testing of tumor tissue
for lack of expression of MMR proteins has an overall
reported sensitivity and speciﬁcity for LS of 83% and
89%, respectively. Additional advantages of IHC
testing include (1) absence of expression of a speciﬁc
mismatch protein can direct germline testing to that
speciﬁc gene and (2) the relative increased prevalence
of MSH-6 mutations in EC which may not exhibit
MSI by molecular analysis. The speciﬁcity of both
MSI and IHC testing in the detection of LS decreases
with increasing age due to increased prevalence of
somatic MLH1 hypermethylation (52–55).
As the majority of cases with MLH1 IHC loss are
due to MLH1 hypermethylation, a sporadic cause of
MLH1 loss,MLH1 hypermethylation analysis should
be undertaken on tumors that show IHC loss of
MLH1 to help triage appropriate cases for germline
testing. It is well documented that MLH1 promoter
hypermethylation analysis is an accurate, cost-effective,
and superior prescreening method compared with
BRAF mutation analysis in the diagnostic algorithm
of LS for EC.MLH1 gene promoter hypermethylation
can be undertaken at low costs in a routine molecular
diagnostic setting, for example, by methylation-speciﬁc
polymerase chain reaction or by methylation-speciﬁc
multiplex ligation-dependent probe ampliﬁcation.
Given the inclusion of patient-derived normal DNA
in the MLH1 promoter hypermethylation, the rare
occurrence of germline MLH1 hypermethylation can
also be detected. The most cost-effective approach
involves screening with MSH-6 and PMS-2 IHC
alone, with subsequent undertaking of MSH-2 and/
or MLH1 IHC and reﬂex MLH1 hypermethylation
when indicated.
The rationale behind universal testing is to reduce
the morbidity and mortality of index patients as well as
relatives of patients with LS. Universal testing for LS in
colorectal cancer (CRC) has been endorsed by the
National Comprehensive Cancer Network. Evaluation
of a universal strategy by Ladabaum et al. (56) revealed
that a systematic application of testing among patients
with newly diagnosed CRC at ≤ 70 yr of age could
provide substantial clinical beneﬁts at acceptable costs.
Other studies have also reported the cost-effectiveness
of universal CRC testing (56). Ladabaum et al. (56)
concluded that IHC testing of CRC for MMR proteins
followed by reﬂex testing of the tumors when MLH1
protein expression is absent emerged as the most cost-
effective approach. These data are not as robust for
EC, but they appear to parallel that for CRC (56).
Approximately 50% of patients with EC with
MMR deﬁciency (not due to MLH1 hypermethyla-
tion) do not harbor an apparent germline mutation.
The cause of such discordance can be attributed to
unidentiﬁed germline mutations, a false positive
MMR deﬁciency test, or biallelic somatic inactivation
of the MMR gene(s). Recent evidence based on
next-generation sequencing suggests that almost 70%
of these tumors harbor biallelic acquired somatic
(tumor) mutations and/or loss of heterozygosity in
MMR genes (57,58). Given the screening implications
associated with a LS-suspected tumor, somatic muta-
tional analysis and loss of heterozygosity should be
considered in the diagnostic algorithm.
Although universal screening testing of EC for
LS is suggested, development and implementation of
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screening programs are complicated. These programs
require cooperation and effective communication across
multiple disciplines, ensuring that patients at risk for LS
are identiﬁed, notiﬁed of abnormal results, and referred
for genetic counseling and genetic testing. Moreover,
the accuracy of IHC is operator dependent and varies
according to the experience and skill of the laboratory
performing the testing. Consequently, it may be that
testing is optimally performed in laboratories with high
volume and high-quality control measures.
Panel testing for germline mutations in > 20 cancer-
causing genes (which include the MMR and EPCAM
genes) is now available commercially as a single test.
Inevitably, advances in technology will decrease the
cost of such analysis. In the future, germline testing,
rather than tumor evaluation, may be the most cost-
effective universal testing approach.
As per the recommendations of the Society of
Gynecologic Oncologists, testing all patients with EC
for LS is recommended. If utilizing this strategy, most
experts would recommend routine tumor-based test-
ing on ECs with IHC followed by methylation testing,
if there is loss of expression of MLH1. Alternatively,
the EC can be initially tested for MSI, but any
abnormality would require the additional step of IHC
and most experts agree that molecular testing by
polymerase chain reaction misses many MSH-6
deﬁcient tumors. Universal tumor testing is likely to
become the future international standard of care and
is already conducted in some hospitals in United
States and elsewhere. However, this standard requires
development of sufﬁcient local and community infra-
structure to appropriately handle genetic results
before implementation, as discussed previously. Con-
sequently, testing could be considered for all patients
with EC 70 yr of age or younger (in corollary to the
CRC recommendations) when appropriate infrastruc-
ture for testing exists. If tumor testing is performed for
those aged 70 yr or younger only, a thorough family
history is essential for those EC patients older than 70
yr; IHC testing should be performed for any
individual whose personal and/or family history fulﬁll
the Amsterdam or Bethesda guidelines or who have a
≥ 5% risk prediction based on the prediction models.
Independent of LS screening, the identiﬁcation of
the MSI (hypermutated)/MMR deﬁcient phenotype in
colorectal (and other) carcinomas has been recently
exploited for targeted immune therapy with anti-
PD-1, as has been mentioned previously. Potential
applications for such targeted therapy in EC have
not been as well investigated, but remain a viable
possibility (59,60).
SUMMARY OF RECOMMENDATIONS
Recommendation 1
The prognostic value of IHC and DNA ploidy in
EC is not clear. It is recommended to perform large
prospective, multicenter studies with good method-
ological quality, to deﬁnitely prove the potential
prognostic utility of these tests.
Level of evidence: IV
Strength of recommendation: C
Recommendation 2
The predictive value of ER and PR IHC in response
to hormone therapy in EC (particularly low-grade
EEC) is not clear. It is recommended to perform large
prospective, multicenter studies with good method-
ological quality, to deﬁnitely prove its potential
predictive value. This should be done, by taking into
account the following variables:
 Different drugs used.
 Differences between low-grade and high-grade
tumors.
 Different methodological and scoring approaches.
 Best tissue type (primary vs. metastatic tumor).
Level of evidence: II
Strength of recommendation: C
Recommendation 3
Validation of molecular tests for diagnosis of EC is
encouraged as an adjunct to diagnosis in endometrial
biopsies. This is particularly potentially interesting in
women with a suspicion of EC and noninformative
endometrial biopsies.
Level of evidence: IV
Strength of recommendation: B
Recommendation 4
Investigational molecular studies are encouraged to
assess the value of next-generation sequencing in
differential diagnosis between different types of EC,
by considering the potential beneﬁts and cost-effec-
tiveness in comparison with IHC and morphologic
analyses.
Level of evidence: IV
Strength of recommendation: C
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Recommendation 5
Mutational analysis of POLE is considered optional
for tailoring treatment in patients with high-grade EC.
Level of evidence: IV
Strength of recommendation: A
Recommendation 6
Combining POLE mutational analysis with IHC
analysis of p53 and MMR proteins (PMS-2 and
MSH-6) is considered optional as a surrogate to
classify tumors into the 4 TCGA groups, particularly
for high-grade EEC and SC.
Level of evidence: IV
Strength of recommendation: A
Recommendation 7
Development of simple molecular tests for POLE
analysis or IHC surrogates of POLE mutation, is
encouraged to allow POLE assessments in pathology
departments with limited molecular pathology facilities.
Level of evidence: IV
Strength of recommendation: C
Recommendation 8
All women who are diagnosed with EC should undergo
systematic clinical screening for LS (review of personal
and family history) and/or IHC/molecular screening.
Level of evidence: III
Strength of recommendation: B
Recommendation 9
IHC screening of EC for LS is the preferred strategy
when resources are available. The most cost-effective
approach involves screening by MSH-6 and PMS-2
IHC alone, with subsequent MSH-2 or MLH1 IHC
when indicated.
Level of evidence: III
Strength of recommendation: B
Recommendation 10
MLH1 hypermethylation analysis should be com-
pleted on tumors that show loss of MLH1 on IHC to
help triage appropriate cases for germline testing.
Level of evidence: I
Strength of recommendation: A
Recommendation 11
Because of the occurrence of potential somatic
mutations in MMR genes, somatic mutation analysis
should be considered if germline testing in appropri-
ately triaged patients is negative.
Level of evidence: IV
Strength of recommendation: B
Recommendation 12
As women with EC with MMR deﬁciency or MSI
(hypermutated) may beneﬁt from immunotherapy,
consideration should be given for MMR deﬁciency
testing for women with EC who are candidates for
chemotherapy.
Level of evidence: IV
Strength of recommendation: B
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